Abstract
Evaluation of the Efficacies of Liraglutide and Glargine in Type 2 Diabetes Patients with Malignant Tumors Treated with Glucocorticoids
Endocrinology Department, Chongqing Yubei District People’s Hospital, Chongqing 401120, 1Department of Endocrinology and Nephrology, Chongqing University Cancer Hospital, School of Medicine, Chongqing University, Shapingba, Chongqing 400044, 2Endocrinology Department, Children’s Hospital of Chongqing Medical University, Yuzhong, Chongqing 400015, 3Endocrinology Department, Dazu Hospital of Chongqing Medical University, The People’s Hospital of Dazu, Chongqing 402360, China
Correspondence Address:
Q. Wu, Endocrinology Department, Dazu Hospital of Chongqing Medical University, The People’s Hospital of Dazu, Chongqing 402360, China, E-mail: wqn11@126.com
To explore the efficacies of liraglutide and glargine in type 2 diabetes patients with malignant tumors treated with glucocorticoids. Overall, 120 patients were recruited, 60 patients were divided into the glargine group (chemotherapy with glucocorticoids and hypoglycemic therapy including glargine) and 60 patients were divided into the liraglutide group (chemotherapy with glucocorticoids and hypoglycemic therapy including liraglutide). Fasting plasma glucose, 2 h postprandial plasma glucose, glycosylated hemoglobin, body mass index, systolic blood pressure, diastolic blood pressure, C peptide, insulin resistance index, insulin secretion index, total cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein, Karnofsky performance status score, rehospitalization rate, average hospitalization days and adverse reactions before and after intervention were compared between the two groups. After treatment, total cholesterol, highdensity lipoprotein, C peptide, systolic blood pressure, diastolic blood pressure and homeostatic model assessment of insulin resistance were not significantly different between the groups. The body mass index, fasting plasma glucose, 2 h postprandial plasma glucose, glycosylated hemoglobin test (A1c) and homeostasis model assessment of beta cell function were significantly lower in the glargine group than the liraglutide group (p<0.05). The hypoglycemia rate was lower in the liraglutide group than the glargine group (p<0.05). The Karnofsky performance status score was increased (p<0.05) and the rehospitalization rate and average hospitalization days (p<0.05) were decreased in the liraglutide group. Pearson and linear regression analyses indicated that liraglutide treatment was associated with better glucose control, a better homeostasis model assessment of beta cell function, hypoglycemia rate and Karnofsky performance status score and reduced rehospitalization rate and average hospitalization days. Liraglutide treatment significantly improved glucose control, homeostasis model assessment of beta cell function and the hypoglycemia rate and Karnofsky performance status score and reduced the rehospitalization rate and average hospitalization days of type 2 diabetes patients with malignant tumors treated with glucocorticoids.
